| P50 | author | Ali Naderi | Q42883590 |
| P2093 | author name string | Ji Liu | |
| | Kee Ming Chia | |
| P2860 | cites work | Development of a second-generation antiandrogen for treatment of advanced prostate cancer | Q24605577 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 |
| | Androgen receptor antagonists (antiandrogens): structure-activity relationships | Q28142737 |
| | Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family | Q28258227 |
| | Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway | Q28284170 |
| | HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer | Q28476604 |
| | BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 |
| | Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy | Q33316645 |
| | Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK | Q33562476 |
| | Estrogen receptor-negative breast cancer: new insights into subclassification and targeting | Q33996918 |
| | The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. | Q34014364 |
| | A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer | Q34551559 |
| | A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. | Q34698933 |
| | HER2 therapy: molecular mechanisms of trastuzumab resistance. | Q35633712 |
| | Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis | Q35872734 |
| | Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops | Q36559220 |
| | Novel concepts in androgen receptor blockade | Q37095836 |
| | In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors | Q37162216 |
| | Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. | Q37384464 |
| | Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer | Q37389790 |
| | Emerging MEK inhibitors. | Q37691441 |
| | A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. | Q38526448 |
| | Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. | Q39683901 |
| | In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 |
| | Nerve growth factor/nuclear factor-kappaB pathway as a therapeutic target in breast cancer. | Q39948754 |
| | Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations | Q40073236 |
| | An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen | Q40313659 |
| | In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates | Q40336852 |
| | Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 |
| | Identification of molecular apocrine breast tumours by microarray analysis. | Q42478400 |
| | PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer | Q42495001 |
| | Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 |
| | Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation | Q43246075 |
| | Expression of androgen receptors in primary breast cancer | Q43249156 |
| | Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. | Q43607758 |
| | Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells | Q44675816 |
| | Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses | Q45178485 |
| | The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. | Q53339475 |
| | EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast | Q83147969 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen-receptor negative breast cancer | Q18553637 |
| P304 | page(s) | R36 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer | |
| P478 | volume | 13 | |